The Crossroads of Lipid Metabolism and Diabetes
Organizer(s): Russell A. DeBose-Boyd, Sudha Biddinger and Alan D. AttieDate: April 19 - 24, 2015
Location: Tivoli Hotel and Congress Center, Copenhagen, Denmark
The prevalence of obesity and Type 2 diabetes are reaching epidemic proportions throughout the world. One of the key features of these insulin-resistant disorders is disturbances in lipid metabolism. Overproduction of fatty acids in the liver leads to hypertriglyceridemia and low HDL cholesterol, which are important risk factors for the development of atherosclerosis, the most common cause of death among diabetic patients. In addition, excess fatty acid production and the accumulation of hepatic cholesterol promote the development of non-alcoholic steatohepatitis (NASH), which has become one of the leading indications for liver transplantation. In addition, disturbances in bile acid metabolism may also contribute to the development of atherosclerosis, as well as gallstones. The goal of this meeting is to provide attendees with the latest advances in the understanding of mechanisms governing the metabolism of lipids and how these pathways become dysregulated in the insulin resistant state. Elucidation of mechanisms underlying lipid metabolism may reveal new therapeutic strategies to combat atherosclerosis and other complications of diabetic patients. This program will stimulate interactions that are likely to augment and accelerate this process.
Scholarship Deadline: December 17 2014
Discounted Abstract Deadline: December 17 2014
Abstract Deadline: January 20 2015
Discounted Registration Deadline: February 18 2015
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Eli Lilly and Company
Isis Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Keystone Symposia thanks our Lead Sponsor for generously supporting this meeting:
We gratefully acknowledge the generous grant for this conference provided by:National Heart, Lung, and Blood Institute (NHLBI)
Grant No. 1R13HL126455-01
Funding for this conference was made possible (in part) by 1R13HL126455-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.